Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

AIDS-related Kaposi sarcoma

WARNING Chemo agent handle w/ caution Uses Hodgkin Dz NHLs, mycosis fungoides, CAs (testis, renal cell, breast, NSCLC), AIDS-related Kaposi sarcoma, choriocarcinoma, histiocytosis Action X Microtubule assembly Dose 0.1-0.5 mg/kg/wk (4-20 mg/m ) X in hepatic failure Caution [D, ] Contra IT use Disp Inj SE i BM (esp leukopenia), NA, constipation, neurotox, alopecia, rash, myalgia, tumor pain Interactions T Effects W/ erythromycin, itraconazole X effects W/ glutamic acid, tryptophan X effects OF phenytoin EMS T Risk of... [Pg.317]

Dezube, B.J. (2000) AIDS-related Kaposi sarcoma the role of local therapy for a systemic disease. Archives of Dermatology, 136, 1554-1556. [Pg.402]

Alitretinoin binds to and activates all known intracellular retinoid receptor substrates. Once activated, these receptors function as transcription factors that regulate the expression of genes that control the process of cellular differentiation and proliferation of both non-rial and neoplastic cells. Alitretinoin is indicated in the topical treatment of AIDS-related Kaposi sarcoma (KS). [Pg.55]

Interferon alfa-2b is an immunomodulator. It causes inhibition of virus replication in virus-infected cells, suppression of cell proliferation, and such immunomodulating activities as enhancement of the phagocytic activity of macrophages and augmentation of the specific cytotoxicity of lymphocytes for target cells. It is indicated in hairy cell leukemia condylomata acuminata AIDS-related Kaposi sarcoma chronic hepatitis B chronic non-A/non-B hepatitis (hepatitis C) and malignant melanoma and follicular non-Hodgkin s lymphoma. [Pg.355]

Liposomal encapsulation of DOX or DNR Preferred anthracycline delivery to the tumor Breast cancer, ovarian cancer, AIDS-related Kaposi s sarcoma, multiple myeloma (pegylated liposomal DOX). Breast cancer (uncoated liposomal DOX). AIDS-related Kaposi s sarcoma, acute mye-loblastic leukemia, multiple myeloma, non-Hodgkin s lymphomas (uncoated liposomal DNR)... [Pg.95]

Ovarian cancer, breast cancer, AIDS-related Kaposi s sarcoma... [Pg.586]

Intron A interferon a-2b Schering-Plough Hairy cell leukemia, genital warts, AIDS-related Kaposi s sarcoma, hepatitis C, hepatitis B, malignant melanoma, follicular lymphoma in conjunction with chemotherapy... [Pg.694]

Hairy cell leukaemia Renal cell carcinoma Basal cell carcinoma Malignant melanoma AIDS-related Kaposi s sarcoma Multiple myeloma Chronic myelogenous leukaemia Non-Hodgkin s lymphoma... [Pg.226]

Hairy cell leukemia Genital warts AIDS-related Kaposi s sarcoma Non-A non-B hepatitis Hepatitis B Malignant melanoma Chronic viral hepatitis C Follicular lymphoma with chemotherapy June 1986 June 1988 Nov. 1988 Feb. 1991 July 1992 Dec. 1995 March 1997 Nov. 1997... [Pg.146]

Cheung TW, Remick SC, Azarnia N, Proper JA, Barrueco JR, Dezube BJ. AIDS-related Kaposi s sarcoma a phase II study of liposomal doxorubicin. The TLC D-99 Study Group. Clin Cancer Res 1999 5 3432. [Pg.47]

Coukell AJ, Spencer CM. Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi s sarcoma. Drugs 1997 53 520. [Pg.47]

Northfelt DW, Dezube BJ, Thommes JA, et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi s sarcoma results of a randomized phase III clinical trial. J Clin Oncol 1998 16 2445. [Pg.48]

Bristol-Myers Squibb Co. manufactures and distributes paclitaxel (brand name, Taxol, and generically known as taxol), which the FDA has approved for treatment of ovarian, breast and lung cancers and AIDs-related Kaposi s sarcoma. Bristol s patent listings in the Orange Book and the related patent infringement suits demonstrate that invalid patents in combination with the lengthy pendency of a patent application can potentially generate an additional 30-month stay. [Pg.119]

There are three liposomal forms of doxorubicin or daunorubicin on the market (Table 8.6). Doxil and DaunoXome have been approved for the treatment of AIDS-related Kaposi s sarcoma and are being evaluated in clinical trials for the treatment of a variety of cancers [148-151]. Evacet (liposomal doxorubicin) has recently been tested in large phase II and III clinical trials for the treatment of metastatic breast cancer and is awaiting approval by the FDA [151], Data obtained from trials thus far suggest that all three liposomal drugs offer significant therapeutic benefit compared with the free drug [113]. [Pg.225]

Northfelt DW, Martin FJ, Working P, Volberding PA, Russell J, Newman M, Amantea MA, Kaplan LD. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi s sarcoma. J Clin Pharmacol 1996 36 55-63. [Pg.202]

Alpha interferon is also effective in the treatment of hairy cell leukaemia, condyloma acuminata (caused by papilloma virus), chronic myelogenous leukaemia and AIDS related Kaposi s sarcoma. [Pg.342]

It is indicated in hairy cell leukemia, AIDS related Kaposi s sarcoma (the detailed pharmacology and its use as antiviral agent is discussed in chapter Antiviral agents ). [Pg.379]

Indications Treatment of chronic hepatitis C, hairy-cell leukemia and AIDS-related Kaposi s sarcoma, as well as for the treatment of chronic phase, Philadelphia chromosome-positive chronic myelogenous leukemia (CML)... [Pg.190]

Recommended dosage and monitoring requirements The recommended dose of Roferon-A for chronic hepatitis C is 3 million international units (MIU) three times a week for 12 months. The recommended dose for CML is 9 MIU daily optimal duration of therapy has not been determined. The recommended dose for hairy cell leukemia is 3 MIU daily for 16 to 24 weeks. The recommended dose for AIDS-related Kaposi s sarcoma is 36 MIU daily for 10 to 12 weeks. There are five types of interferon alfa currently available in the United States interferon alfa-2a, peginterferon alfa-2a, interferon alfa-2b, interferon alfacon-1, and interferon alfa n3. Doses are not consistent for these preparations. [Pg.190]

E. Therapeutic response According to the product label, studies have shown that Rofewn-A can normalize serum transaminases, improve Uver histology, and reduce viral load in patients with chronic hepatitis C virus (HCV) infection. Other studies have shown that Roferon-A can produce clinically meaningful tumor regression or disease stabilization in patients with hairy-cell leukemia or in patients with AIDS-related Kaposi s sarcoma. In Ph-positive CML, Roferon-A supplemented with intermittent chemotherapy has been shown to prolong overall survival and to delay disease progression compared to patients treated with chemotherapy alone. In addition Roferon-A has been shown to produce sustained complete cytogenetic responses in a small subset of patients with CML in chronic phase. [Pg.191]

F. Role in therapy According to Micromedex, Roferon-A is recommended as the drug of choice in renal carcinoma and the chronic phase of chronic myelogenous leukemia. The role of Gleevec (Ima-tinib) in CML is yet to be determined, but it may replace the use of interferon alfa-2a. Roferon-A is an alternative (for unrespon-sive/intolerant patients) to current regimens of choice in hairy-cell leukemia, multiple myeloma, metastatic melanoma, and AIDS-related Kaposi s sarcoma. Other alpha interferons appear to have similar efficacy and can be used in lieu of Roferon-A in some instances. In particular, interferon alfa-2b (Intron) can be considered to have the same role as interferon alfa-2a in chronic hepatitis C, Kaposi s sarcoma, and hairy-cell leukemia. [Pg.191]

H. Other considerations Interferon alfa-2a has been designated an orphan drug product for the treatment of chronic myelogenous leukemia, AIDS-related Kaposi s sarcoma, renal cell carcinoma, metastatic malignant melanoma, and esophageal and colorectal cancer. [Pg.192]

Indications Treatment of patients with hairy-cell leukemia, malignant melanoma, follicular non-Hodgkin s lymphoma (NHL), AIDS-related Kaposi s sarcoma, chronic hepatitis C, and the skin disorder, condylomata acuminata... [Pg.192]

Alitretinoin (Panretin) is a topical formulation of 9-c/s-retinoic acid which is approved for the treatment of cutaneous lesions in patients with AIDS-related Kaposi s sarcoma. Localized reactions may include intense erythema, edema, and vesiculation necessitating discontinuation of therapy. Patients who are applying alitretinoin should not concurrently use... [Pg.1305]

Taxol is a natural product that has impacted the lives of hundreds of thousands of people. Since 1992, it has been the API in certain chemotherapy agents provided to patients suffering from a variety of cancers and is approved for the treatment of ovarian, breast, non-smaU-ceU lung cancers and AIDS-related Kaposi s sarcoma in over 50 countries. [Pg.145]

See other pages where AIDS-related Kaposi sarcoma is mentioned: [Pg.317]    [Pg.15]    [Pg.513]    [Pg.317]    [Pg.15]    [Pg.513]    [Pg.21]    [Pg.238]    [Pg.238]    [Pg.235]    [Pg.211]    [Pg.460]    [Pg.579]    [Pg.162]    [Pg.169]    [Pg.192]    [Pg.192]    [Pg.1177]    [Pg.238]   
See also in sourсe #XX -- [ Pg.55 ]



SEARCH



Kaposi sarcoma

© 2024 chempedia.info